Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Esperion TherapeuticsESPR -0.31%62 Days Inventory is 276.25 as of Mar. 2026, which is 38% below its 10-year median of 448.47. GuruFocus rates ESPR with a GF Score™ of 62/100 and a GF Value™ of $2.30 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 923 Drug Manufacturers companies, Esperion Therapeutics ranks worse than 83.42% on this metric.
The historical rank and industry rank for Esperion Therapeutics's Days Inventory or its related term are showing as below:
ESPR'
s Days Inventory Range Over the Past 10 Years
Min: 281.91 Med: 448.47 Max: 2462.22
Current: 293.45
During the past 13 years, Esperion Therapeutics's highest Days Inventory was 2462.22. The lowest was 281.91. And the median was 448.47.
ESPR's Days Inventory is ranked worse than 83.42% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.87
vs ESPR: 293.45
Esperion Therapeutics's Days Inventory
declined
from Mar. 2025 (280.38) to Mar. 2026 (276.25).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Esperion Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.33.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Esperion Therapeutics's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.31.
Esperion Therapeutics (NAS:ESPR) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Esperion Therapeutics's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Esperion Therapeutics's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Esperion Therapeutics Days Inventory Related Terms
Esperion Therapeutics Days Inventory Historical Data
* Premium members only.
The historical data trend for Esperion Therapeutics's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ESPR vs AMPH, NIKA, BIOA: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Esperion Therapeutics Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Days Inventory distribution charts can be found below:
* The bar in red indicates where Esperion Therapeutics's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Esperion Therapeutics (ESPR) has a Days Inventory of 276.25 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Esperion Therapeutics and its competitors. This is 38% below median its historical median of 448.47. Over the past decade, Esperion Therapeutics' Days Inventory has ranged from 281.91 to 2,462.22. According to the industry distribution chart, Esperion Therapeutics ranks #770 out of 923 companies in the Drug Manufacturers industry, placing it in the top 83.4%.
Is Esperion Therapeutics' Days Inventory too high?
Esperion Therapeutics' current Days Inventory of 276.25 is 38% below median its 10-year median of 448.47. Over the past 10 years, this metric has ranged from a low of 281.91 to a high of 2,462.22. The Drug Manufacturers industry median Days Inventory is 164.87. Esperion Therapeutics' value of 276.25 is 67.6% above this industry median. Based on the distribution chart, Esperion Therapeutics ranks #770 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Esperion Therapeutics has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Esperion Therapeutics' Days Inventory compare to AMPH and NIKA?
According to the Drug Manufacturers industry distribution chart, Esperion Therapeutics ranks #770 out of 923 companies for Days Inventory. This places Esperion Therapeutics in the lower half of its industry. The industry median Days Inventory is 164.87. Esperion Therapeutics' value of 276.25 is 67.6% above this benchmark. Historically, Esperion Therapeutics' own Days Inventory has ranged from 281.91 to 2,462.22 over the past decade. While the company's 10-year median is 448.47 vs. the industry median of 164.87, Esperion Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.87, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Esperion Therapeutics's current Days Inventory of 276.25 is 67.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Esperion Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Esperion Therapeutics's current Days Inventory is 276.25, which is 38% below median its own 10-year median of 448.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Esperion Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Esperion Therapeutics (ESPR) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.30, compared to a current price of $3.18 — trading 38.3% above its estimated fair value. The current Days Inventory is 276.25, which is 38% below median its 10-year median of 448.47 and 67.6% above the Drug Manufacturers industry median of 164.87. Esperion Therapeutics' overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Esperion Therapeutics (ESPR), the current Days Inventory is 276.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Esperion Therapeutics (ESPR) Overvalued in 2026?
Based on GuruFocus' analysis, Esperion Therapeutics stock appears to be overvalued.
The current stock price of $3.18 is trading 38.3% above its estimated GF Value™ of $2.30.
GuruFocus considers Esperion Therapeutics to be Significantly Overvalued.
Key valuation signals for ESPR:
Days Inventory: 276.25 (38% below median its 10-year median of 448.47)
GF Value™: $2.30 vs. price of $3.18 (38.3% above fair value)
Industry Position: 67.6% above the Drug Manufacturers median (#770 of 923)
No single metric tells the full story. See the ESPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
62GF Score
Get the complete analysis for ESPR
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ESPR has been successfully added to your 
